Emmet McCormack

Emmet McCormack is a Professor in the Clinical Department 2 at the University of Bergen, Norway, with a dual research focus spanning cancer immunotherapy and science education in pharmaceutical contexts.

His primary research concentrates on developing innovative immunotherapies for myeloid neoplasia using preclinical models, alongside creating advanced drug delivery systems like hyaluronic acid-coated carriers for localized cancer treatment. Concurrently, he investigates problem-based learning methodologies to enhance laboratory education, specifically targeting student confidence, agency, and cognitive reflection in pharmaceutical training environments.

Analysis of his recent publications reveals a clear bifurcation in scholarly output: therapeutic advancements in CAR T-cell protocols and AML vaccine development dominate his cancer research, while educational innovations in laboratory pedagogy characterize his science education contributions. This duality demonstrates significant translational impact across both biomedical therapy and academic training domains.

McCormack actively leads and participates in major research initiatives including the active project 'Innovative Adaptive Immunotherapy using new animal models' (IIDEA) and completed projects such as 'translational development of preclinical models and therapies in myeloid neoplasia' and 'AML vaccine', indicating substantial grant acquisition and management capabilities.

He operates within multidisciplinary research collectives comprising 4-11 collaborators per project, as evidenced by initiatives like 'Animal Model for evaluation of Innovative immunotherapy Designs' (AMIDE) and 'ISPIC', facilitating cross-institutional work between University of Bergen (UIB), Oslo University Hospital (OUS), and other Nordic research entities.